文献速递肝病

受控衰减参数测定的肝脂肪变与慢性乙型肝炎纤维化负担的关联

Association Between Hepatic Steatosis, Measured by Controlled Attenuation Parameter, and Fibrosis Burden in Chronic Hepatitis B.
PubMed 文献 · Clin Gastroenterol Hepatol · 2017-09-29

该研究在香港1606例慢性乙型肝炎患者中采用瞬时弹性成像及受控衰减参数(CAP)评估肝脂肪变与肝纤维化,发现重度脂肪变与重度纤维化相关,在初治患者中比值比为3.60(95%CI 1.21-10.75),在接受治疗者中亦相关,结论需纵向研究验证脂肪变控制能否减轻纤维化负担。

要点

  • 队列中脂肪变、重度脂肪变、重度纤维化患病率分别为40.8%、22.6%、14.1%。
  • 重度脂肪变患者中重度纤维化比例21.4%,高于总体队列的11.9%(P<.001)。
  • CAP每增加10 dB/m,初治患者重度纤维化风险增加15%,治疗患者增加7%-8%。

核心结论

  • CAP测定的重度脂肪变与初治及接受治疗的慢性乙型肝炎患者的重度纤维化相关。
  • 需要纵向研究探讨在抗病毒治疗之外控制脂肪变是否能减轻慢性乙型肝炎患者的纤维化负担。

研究设计与样本

  • 研究于2015年1月至2016年9月在香港纳入1606例慢性乙型肝炎患者,其中898例接受核苷(酸)类似物治疗,中位治疗时间75.4个月。
  • 采用瞬时弹性成像测量肝硬度并测定CAP,同时收集病史、当前治疗、吸烟饮酒习惯、人体测量学指标并分析空腹血样。
  • 重度肝纤维化按指南定义:丙氨酸氨基转移酶(ALT)正常者肝硬度>9.0 kPa,ALT为正常上限1-5倍者肝硬度>12.0 kPa。
  • 脂肪变定义为CAP≥248 dB/m,重度脂肪变定义为CAP≥280 dB/m。
  • 采用多因素分析识别与重度纤维化相关的因素。

主要发现

  • 队列中脂肪变患病率为40.8%,重度脂肪变为22.6%,重度纤维化为14.1%。
  • 重度脂肪变患者中重度纤维化比例为21.4%,总体队列为11.9%(P<.001)。
  • 多因素分析中,初治患者重度脂肪变与重度纤维化相关,比值比3.60(95%CI 1.21-10.75)。
  • 接受治疗者中,治疗≥3年者比值比1.95(95%CI 1.06-3.61),≥5年者2.28(95%CI 1.13-4.61),≥7年者2.79(95%CI 1.17-6.62)。
  • CAP每增加10 dB/m,初治患者重度纤维化风险增加15%,接受治疗患者增加7%-8%。

关键数值与推荐

  • 重度肝纤维化:ALT正常者肝硬度>9.0 kPa,ALT为正常上限1-5倍者肝硬度>12.0 kPa。
  • 脂肪变:CAP≥248 dB/m;重度脂肪变:CAP≥280 dB/m。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出需要纵向研究来探讨控制脂肪变能否在抗病毒治疗之外减轻慢性乙型肝炎患者的纤维化负担。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The interaction between chronic hepatitis B (CHB) and hepatic steatosis is poorly understood. We investigated whether measurement of controlled attenuation parameter (CAP), a non-invasive method to quantify steatosis, can assist in monitoring patients with CHB. METHODS: We performed transient elastography, to measure liver stiffness, and made CAP measurements in 1606 patients with CHB (898 treated with nucleoside analogues, for a median 75.4 months) in Hong Kong, from January 2015 through September 2016. We also collected information on patients' medical history, current treatment, and smoking and alcohol habits, anthropometric measurements. We obtained and analyzed fasting blood samples. Severe liver fibrosis was defined, according to guidelines, as a liver stiffness measurement greater than 9.0 kPa in patients with normal level of alanine aminotransferase (ALT) or greater than 12.0 kPa in patients with a level of ALT 1-5-fold the upper limit of normal. Steatosis was defined as a CAP measurement of 248 dB/m or more, and severe steatosis as a CAP measurement or 280 dB/m more. We performed multivariate analysis to identify factors associated with severe fibrosis. RESULTS: The prevalence of steatosis, severe steatosis, and severe fibrosis in our cohort were 40.8%, 22.6%, and 14.1%, respectively. A higher proportion of patients with severe steatosis had severe fibrosis (21.4% vs 11.9% in the overall cohort; P < .001). In multivariate analysis, severe steatosis was associated with severe fibrosis in treatment-naïve patients (odds ratio, 3.60, 95% CI, 1.21-10.75) and in patients receiving treatment (odds ratios: 1.95 [1.06-3.61] for 3 or more years of treatment, 2.28 [1.13-4.61] for 5 or more years of treatment, and 2.79 [1.17-6.62] for 7 or more years of treatment). With every increase in CAP value of 10 dB/m, the risk of severe fibrosis increased by 15% in treatment-naïve patients and by 7%-8% in patients receiving treatment. CONCLUSIONS: Severe steatosis, determined by CAP measurement, is associated with severe fibrosis in treatment-naïve patients with CHB and in patients receiving treatment. Longitudinal studies are required to investigate if steatosis control, in addition to antiviral treatment, can reduce the burden fibrosis in patients with CHB.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Seto WK, Hui RWH, Mak LY, et al. Association Between Hepatic Steatosis, Measured by Controlled Attenuation Parameter, and Fibrosis Burden in Chronic Hepatitis B. Clin Gastroenterol Hepatol. 2017. PMID: 28970146. doi:10.1016/j.cgh.2017.09.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。